Esophagogastric Junction Adenocarcinoma research hub

A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma

This study is testing a new combination treatment for stomach or gullet cancer that can be removed with surgery. It combines a drug called Tislelizumab with standard chemotherapy (FLOT) given before the operation. We want to see if this new approach is safe and works well.